Cargando…

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

BACKGROUND: Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations may provide a minimally invasive means to dynamically assess tumour burden and response to treatment in cancer patients. Somatic TP53 mutations are a defining feature of high-grade serous ovarian carcinoma (HGSO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parkinson, Christine A., Gale, Davina, Piskorz, Anna M., Biggs, Heather, Hodgkin, Charlotte, Addley, Helen, Freeman, Sue, Moyle, Penelope, Sala, Evis, Sayal, Karen, Hosking, Karen, Gounaris, Ioannis, Jimenez-Linan, Mercedes, Earl, Helena M., Qian, Wendi, Rosenfeld, Nitzan, Brenton, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172526/ https://www.ncbi.nlm.nih.gov/pubmed/27997533 http://dx.doi.org/10.1371/journal.pmed.1002198

Ejemplares similares

Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
por: Schwarz, Roland F., et al.
Publicado: (2015)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Deen, Surrin S., et al.
Publicado: (2019)

Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer
por: Deen, Surrin S., et al.
Publicado: (2019)

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2023)

Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy
por: Deen, Surrin S, et al.
Publicado: (2022)

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients
por: Risberg, Bente, et al.
Publicado: (2018)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
por: Rundo, Leonardo, et al.
Publicado: (2022)

Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene
por: Mittempergher, Lorenza, et al.
Publicado: (2020)

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2010)

Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier
por: Martins, Filipe C, et al.
Publicado: (2014)

Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma
por: Gill, Andrew B., et al.
Publicado: (2020)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer
por: Martin-Gonzalez, Paula, et al.
Publicado: (2020)

Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T(1) and T(2) Mapping in a PET/MR Setting
por: Kaggie, Joshua D., et al.
Publicado: (2019)

Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
por: Martins, Filipe Correia, et al.
Publicado: (2022)

Laparoscopic resection of single site pelvic side wall recurrence 6 years after stage IIIc high grade serous primary peritoneal cancer
por: Addley, Susan, et al.
Publicado: (2021)

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models
por: Sauer, Carolin M, et al.
Publicado: (2022)

Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma
por: Veeraraghavan, Harini, et al.
Publicado: (2020)

High-grade serous ovarian carcinoma organoids as models of chromosomal instability
por: Vias, Maria, et al.
Publicado: (2023)

Non-contrast MRI can accurately characterize adnexal masses: a retrospective study
por: Sahin, Hilal, et al.
Publicado: (2021)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Central Serous Chorioretinopathy Development following Cessation of Terbinafine Treatment
por: Shmueli, Or, et al.
Publicado: (2022)

Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
por: Montfort, Anne, et al.
Publicado: (2020)

Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis
por: Beer, Lucian, et al.
Publicado: (2020)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer
por: Beer, Lucian, et al.
Publicado: (2020)

Ovarian cancer: imaging in treatment selection and planning with FIGO update
por: Sala, Evis
Publicado: (2014)

Ovarian cancer: imaging in treatment selection and planning with FIGO update
por: Sala, Evis
Publicado: (2015)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series
por: Kasherman, Lawrence, et al.
Publicado: (2021)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
por: Biatta, Chiara M., et al.
Publicado: (2023)

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
por: Goranova, T, et al.
Publicado: (2017)

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium
por: Goranova, T, et al.
Publicado: (2019)

Conditions Associated with Circulating Tumor-Associated Folate Receptor 1 Protein in Healthy Men and Women
por: Kelemen, Linda E., et al.
Publicado: (2014)

Retinal Imaging and Optical Coherence Tomography of Choroidal Haemangioma Mimicking Central Serous Chorioretinopathy
por: Jugnarain, Davina, et al.
Publicado: (2023)

Structured reporting of pelvic MRI leads to better treatment planning of uterine leiomyomas
por: Sala, Evis, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6piqiqpk8gkocpst1i3ndkpn3o